Skip to main content

Revised Geneva Score

The Revised Geneva Score is an objective clinical prediction rule for suspected pulmonary embolism. It stratifies patients into low, intermediate, or high probability groups using standardized variables without subjective gestalt criteria.

Formula: Revised Geneva = sum of objective PE risk criteria (score range 0-22).

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

How It Works

1

Score 9 objective clinical variables

Assess nine variables entirely from history and physical exam — no labs or imaging required: age >65, prior DVT/PE, surgery or fracture in the past month, active malignancy, unilateral lower limb pain, hemoptysis, heart rate 75–94 bpm, heart rate ≥95 bpm, and pain on deep vein palpation plus unilateral edema. Each item carries a defined point weight.

2

Sum the total points (0–22)

Add up all applicable points. The maximum total is 22 points. Unlike the Wells PE score, every item in the Revised Geneva Score is fully objective — there is no subjective clinician-gestalt item, making the score reproducible across providers and settings.

3

Interpret probability and choose the next diagnostic step

Low probability (0–3): PE prevalence approximately 8% — combine with D-dimer; negative result excludes PE. Intermediate probability (4–10): PE prevalence approximately 28% — D-dimer first; positive result requires CT-PA. High probability (≥11): PE prevalence approximately 74% — proceed directly to CT-PA without D-dimer testing.

Who Uses the Revised Geneva Score

Emergency PE Evaluation Before CT

Emergency physicians, hospitalists

Apply Revised Geneva Score before ordering CT pulmonary angiography to determine whether D-dimer testing can safely replace imaging. Low-probability patients with negative D-dimer do not require CT-PA, reducing radiation exposure and contrast use.

Deciding Need for D-dimer Testing

Emergency and primary care physicians

In low- and intermediate-probability patients, Revised Geneva Score combined with high-sensitivity D-dimer achieves >97% sensitivity for PE exclusion. The score guides whether D-dimer testing is the appropriate next step or whether direct CT-PA is warranted.

Pulmonary Embolism Response Team (PERT) Activation

PERT coordinators, emergency physicians

High-probability Revised Geneva Score (≥11) is one indicator for early PERT activation in institutions with formal PE response programs, particularly when hemodynamic instability is present or massive PE is suspected.

Reducing Unnecessary CT-PA in Low-Risk Patients

Emergency departments, radiology stewardship teams

Systematic use of Revised Geneva Score in PE diagnostic pathways reduces CT-PA utilization by 30–50% in low-probability patients, decreasing radiation exposure, contrast nephropathy risk, and incidental findings that trigger further workup.

Clinical Research PE Probability Assessment

Clinical researchers, trialists

The fully objective nature of the Revised Geneva Score makes it the preferred pre-test probability tool in clinical trials and research protocols where reproducibility across sites and investigators is essential.

Standardized Inter-Provider Communication

Emergency teams, rapid response teams

Because Revised Geneva Score eliminates subjective gestalt items, it enables consistent PE probability communication between providers, trainees, and across handoffs — particularly in high-volume or teaching environments.

Pro Tips

1

Revised Geneva is fully objective — unlike Wells PE

The key advantage of Revised Geneva over Wells PE is that it contains no subjective 'PE most likely diagnosis' item. This makes it more reproducible across providers and less dependent on clinical experience, which is especially valuable in training environments and multi-provider settings.

2

Low probability + negative D-dimer = PE excluded without CT-PA

When Revised Geneva Score is 0–3 (low probability) and high-sensitivity D-dimer is negative, the sensitivity for PE exclusion exceeds 97% based on prospective validation. This combination safely avoids CT-PA in a substantial proportion of suspected PE patients.

3

Use age-adjusted D-dimer in patients over 50

For patients aged >50 years with low or intermediate Revised Geneva probability, use age-adjusted D-dimer (age × 10 µg/L FEU) instead of the fixed 500 µg/L threshold. This increases specificity by approximately 25–30% in elderly patients while maintaining sensitivity above 97%.

4

Intermediate probability + elevated D-dimer = CT-PA required

Patients with Revised Geneva 4–10 (intermediate probability) and a positive D-dimer result require CT pulmonary angiography. There is no validated combination in this group that allows safe PE exclusion without imaging.

5

High probability: proceed directly to CT-PA — skip D-dimer

In high-probability patients (Revised Geneva ≥11), D-dimer testing is not useful — even a negative result does not safely exclude PE due to high pretest probability. Proceed directly to CT-PA. If CT-PA is delayed or unavailable, ventilation-perfusion (V/Q) scan is an alternative.

6

YEARS algorithm as an alternative with fewer variables

The YEARS algorithm (3 items + D-dimer with a dual threshold) is an alternative diagnostic strategy that may exclude even more patients from CT-PA than Revised Geneva + D-dimer. Both are endorsed by ESC 2019 PE Guidelines as valid diagnostic pathways.

7

Start anticoagulation at high clinical suspicion if bleeding risk allows

In high-probability Revised Geneva Score with clinical deterioration or delay to CT-PA, consider initiating therapeutic anticoagulation (LMWH or UFH) before imaging confirmation, provided there is no contraindication to anticoagulation.

8

CT-PA is the gold standard — sensitivity 94–96%, specificity 97–99%

CT pulmonary angiography remains the definitive imaging test for PE. In hemodynamically unstable patients with suspected massive PE, bedside echocardiography can be used as a bridge to identify right ventricular strain before CT-PA.

9

Consider alternative diagnoses before diagnosing PE

Before labeling chest pain or dyspnea as PE, consider pneumothorax (sudden onset, absent breath sounds), pericarditis (positional chest pain, friction rub, diffuse ST elevation), and ACS (ischemic ECG changes, troponin rise). These can coexist with or mimic PE.

10

Bilateral compression ultrasound if CT-PA unavailable

If CT-PA is contraindicated (severe contrast allergy, pregnancy, renal failure) or unavailable, bilateral lower extremity compression ultrasound can confirm DVT in a patient with high clinical suspicion for PE. Confirmed DVT in this context warrants anticoagulation.

Common Questions About Your Results

Evidence-Based Methodology

Revised Geneva Score published by Le Gal et al. (Ann Intern Med 2006) from 965 patients. Prospective validation by Klok et al. (J Thromb Haemost 2008). Sensitivity for low-probability PE + negative D-dimer ≈ 97%. ESC 2019 PE Guidelines (Konstantinides et al., Eur Heart J 2020) endorse Revised Geneva alongside Wells score for PE probability assessment. Age-adjusted D-dimer: Righini et al. (JAMA 2014) — 30% increase in specificity without reducing sensitivity.

Clinical Content Trust

Last reviewed:
April 21, 2026
Guideline version:
General evidence framework v2026.04
Source set version:
Primary-source set v1

How to Interpret Your Result

The Revised Geneva result estimates PE probability before imaging. Low scores generally support D-dimer-first strategies, while high scores typically warrant direct imaging.

It is a pathway tool and should be interpreted with symptoms, hemodynamics, and clinical context.

When to Use This Tool

Use Revised Geneva in adults with suspected pulmonary embolism when you need an objective pretest probability framework to guide D-dimer versus direct imaging decisions.

It is particularly useful where standardized, reproducible scoring is preferred across teams.

Limitations

Revised Geneva does not include clinician gestalt and may underperform in atypical presentations. It should not delay urgent imaging in unstable patients.

As with other pretest scores, accuracy depends on correct data capture and appropriate pathway selection.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

  1. April 21, 2026 · trust-baseline

    Clinical trust metadata enabled for this tool page with structured review/version fields.

Frequently Asked Questions